Bioventus Net Income
| BVS Stock | USD 8.27 0.17 2.10% |
As of the 14th of February 2026, Bioventus shows the Mean Deviation of 1.93, risk adjusted performance of 0.0551, and Downside Deviation of 2.54. Bioventus technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Bioventus coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Bioventus is priced correctly, providing market reflects its regular price of 8.27 per share. Given that Bioventus has jensen alpha of 0.0955, we suggest you to validate Bioventus's prevailing market performance to make sure the company can sustain itself at a future point.
Bioventus Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.4583 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -286.2 K | -300.5 K | |
| Net Income Applicable To Common Shares | 22.3 M | 23.4 M | |
| Net Loss | -39.4 M | -41.4 M | |
| Net Loss | (0.59) | (0.62) | |
| Net Income Per E B T | 0.79 | 1.00 |
Bioventus | Net Income | Build AI portfolio with Bioventus Stock |
The evolution of Net Income for Bioventus provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Bioventus compares to historical norms and industry peers.
Latest Bioventus' Net Income Growth Pattern
Below is the plot of the Net Income of Bioventus over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Bioventus financial statement analysis. It represents the amount of money remaining after all of Bioventus operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Bioventus' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bioventus' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (318 K) | 10 Years Trend |
|
Net Income |
| Timeline |
Bioventus Net Income Regression Statistics
| Arithmetic Mean | (31,529,529) | |
| Geometric Mean | 22,044,679 | |
| Coefficient Of Variation | (159.04) | |
| Mean Deviation | 30,192,535 | |
| Median | (22,367,000) | |
| Standard Deviation | 50,145,239 | |
| Sample Variance | 2514.5T | |
| Range | 178.1M | |
| R-Value | (0.30) | |
| Mean Square Error | 2442.4T | |
| R-Squared | 0.09 | |
| Significance | 0.24 | |
| Slope | (2,968,853) | |
| Total Sum of Squares | 40232.7T |
Bioventus Net Income History
Other Fundumenentals of Bioventus
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Bioventus Net Income component correlations
Bioventus Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Bioventus is extremely important. It helps to project a fair market value of Bioventus Stock properly, considering its historical fundamentals such as Net Income. Since Bioventus' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bioventus' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bioventus' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Health Care Equipment & Supplies market expansion? Will Bioventus introduce new products? Factors like these will boost the valuation of Bioventus. Projected growth potential of Bioventus fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Bioventus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.16 | Revenue Per Share | Quarterly Revenue Growth (0) | Return On Assets | Return On Equity |
Understanding Bioventus requires distinguishing between market price and book value, where the latter reflects Bioventus's accounting equity. The concept of intrinsic value - what Bioventus' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Bioventus' price substantially above or below its fundamental value.
It's important to distinguish between Bioventus' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bioventus should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Bioventus' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Bioventus 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Bioventus' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Bioventus.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Bioventus on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Bioventus or generate 0.0% return on investment in Bioventus over 90 days. Bioventus is related to or competes with Treace Medical, Orthopediatrics Corp, Standard Biotools, CeriBell, Butterfly Network, Varex Imaging, and Cytek Biosciences. Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and e... More
Bioventus Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Bioventus' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Bioventus upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.54 | |||
| Information Ratio | 0.034 | |||
| Maximum Drawdown | 17.83 | |||
| Value At Risk | (3.86) | |||
| Potential Upside | 4.99 |
Bioventus Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bioventus' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Bioventus' standard deviation. In reality, there are many statistical measures that can use Bioventus historical prices to predict the future Bioventus' volatility.| Risk Adjusted Performance | 0.0551 | |||
| Jensen Alpha | 0.0955 | |||
| Total Risk Alpha | (0.05) | |||
| Sortino Ratio | 0.0369 | |||
| Treynor Ratio | 0.1583 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bioventus' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Bioventus February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0551 | |||
| Market Risk Adjusted Performance | 0.1683 | |||
| Mean Deviation | 1.93 | |||
| Semi Deviation | 2.28 | |||
| Downside Deviation | 2.54 | |||
| Coefficient Of Variation | 1681.69 | |||
| Standard Deviation | 2.75 | |||
| Variance | 7.57 | |||
| Information Ratio | 0.034 | |||
| Jensen Alpha | 0.0955 | |||
| Total Risk Alpha | (0.05) | |||
| Sortino Ratio | 0.0369 | |||
| Treynor Ratio | 0.1583 | |||
| Maximum Drawdown | 17.83 | |||
| Value At Risk | (3.86) | |||
| Potential Upside | 4.99 | |||
| Downside Variance | 6.46 | |||
| Semi Variance | 5.19 | |||
| Expected Short fall | (2.03) | |||
| Skewness | 0.7494 | |||
| Kurtosis | 2.93 |
Bioventus Backtested Returns
Bioventus appears to be somewhat reliable, given 3 months investment horizon. Bioventus secures Sharpe Ratio (or Efficiency) of 0.11, which signifies that the company had a 0.11 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Bioventus, which you can use to evaluate the volatility of the firm. Please makes use of Bioventus' Downside Deviation of 2.54, mean deviation of 1.93, and Risk Adjusted Performance of 0.0551 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Bioventus holds a performance score of 8. The firm shows a Beta (market volatility) of 0.97, which signifies possible diversification benefits within a given portfolio. Bioventus returns are very sensitive to returns on the market. As the market goes up or down, Bioventus is expected to follow. Please check Bioventus' semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Bioventus' price patterns will revert.
Auto-correlation | 0.44 |
Average predictability
Bioventus has average predictability. Overlapping area represents the amount of predictability between Bioventus time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Bioventus price movement. The serial correlation of 0.44 indicates that just about 44.0% of current Bioventus price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.44 | |
| Spearman Rank Test | 0.26 | |
| Residual Average | 0.0 | |
| Price Variance | 0.08 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Bioventus Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Bioventus reported net income of (318,000). This is 100.09% lower than that of the Health Care Equipment & Supplies sector and 100.13% lower than that of the Health Care industry. The net income for all United States stocks is 100.06% higher than that of the company.
Bioventus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bioventus' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bioventus could also be used in its relative valuation, which is a method of valuing Bioventus by comparing valuation metrics of similar companies.Bioventus is currently under evaluation in net income category among its peers.
Bioventus Current Valuation Drivers
We derive many important indicators used in calculating different scores of Bioventus from analyzing Bioventus' financial statements. These drivers represent accounts that assess Bioventus' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Bioventus' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 724.2M | 658.9M | 160.2M | 330.2M | 379.7M | 360.7M | |
| Enterprise Value | 825.7M | 972.6M | 548.1M | 688.0M | 791.2M | 1.1B |
Bioventus ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bioventus' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bioventus' managers, analysts, and investors.Environmental | Governance | Social |
Bioventus Institutional Holders
Institutional Holdings refers to the ownership stake in Bioventus that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Bioventus' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bioventus' value.| Shares | Dimensional Fund Advisors, Inc. | 2025-06-30 | 671.8 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 652.9 K | Millennium Management Llc | 2025-06-30 | 606 K | Oberweis Asset Management Inc | 2025-06-30 | 601.7 K | Charles Schwab Investment Management Inc | 2025-06-30 | 419.9 K | Qube Research & Technologies | 2025-06-30 | 418.6 K | Northern Trust Corp | 2025-06-30 | 394.2 K | Aqr Capital Management Llc | 2025-06-30 | 389.3 K | Kent Lake Pr Llc | 2025-06-30 | 350 K | Essex Woodlands Health Ventures | 2025-06-30 | 13 M | Juniper Investment Co, Llc | 2025-06-30 | 6.9 M |
Bioventus Fundamentals
| Return On Equity | 0.0638 | ||||
| Return On Asset | 0.0414 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 822.26 M | ||||
| Shares Outstanding | 66.98 M | ||||
| Shares Owned By Insiders | 11.71 % | ||||
| Shares Owned By Institutions | 75.22 % | ||||
| Number Of Shares Shorted | 1.55 M | ||||
| Price To Earning | 6.96 X | ||||
| Price To Book | 3.26 X | ||||
| Price To Sales | 0.96 X | ||||
| Revenue | 573.28 M | ||||
| Gross Profit | 382.03 M | ||||
| EBITDA | 39.22 M | ||||
| Net Income | (318 K) | ||||
| Cash And Equivalents | 34.36 M | ||||
| Cash Per Share | 0.56 X | ||||
| Total Debt | 335.63 M | ||||
| Debt To Equity | 1.17 % | ||||
| Current Ratio | 0.94 X | ||||
| Book Value Per Share | 2.48 X | ||||
| Cash Flow From Operations | 38.8 M | ||||
| Short Ratio | 6.82 X | ||||
| Earnings Per Share | 0.16 X | ||||
| Price To Earnings To Growth | 1.02 X | ||||
| Target Price | 14.5 | ||||
| Number Of Employees | 950 | ||||
| Beta | 0.79 | ||||
| Market Capitalization | 542.51 M | ||||
| Total Asset | 727.96 M | ||||
| Retained Earnings | (355.08 M) | ||||
| Working Capital | 65.21 M | ||||
| Net Asset | 727.96 M |
About Bioventus Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bioventus's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bioventus using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bioventus based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bioventus Stock Analysis
When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.